|Soluble CD40 ligand and prolactin levels in migraine patients during interictal period.|
|Jump to Full Text|
|PMID: 21331754 Owner: NLM Status: MEDLINE|
|The relationship of migraine with cardiovascular diseases has been clarified by many studies, and currently, migraine is suggested to be a systematic vasculopathy. Inflammation, thrombosis and impaired vascular reactivity are the underlying pathophysiological mechanisms of the vasculopathy. In the present study, we aimed to investigate the relationship between prolactin levels and subclinical atherosclerosis risk factors such as soluble CD40 ligand (sCD40L) and high-sensitivity CRP (hsCRP) in migraine patients during interictal period. Fifty female migraine patients and age-matched 25 female control cases were enrolled in the study. Migraine diagnosis was settled according to the ICHD-II diagnostic criteria. A questionnaire was completed about the existence of vascular risk factors. Serum samples were used to measure sCD40L, hsCRP and prolactin levels. No difference was found between the prolactin levels of the migraine patients and the controls. The sCD40L levels were significantly higher in migraine patients (p < 0.001). High-sensitivity CRP levels showed no difference between the groups. There was no correlation between prolactin, sCD40L, and hs-CRP levels in migraine patients. We consider that the migraine patients are prone to subclinical atherosclerosis, but this tendency is independent of prolactin levels.|
|Sibel Guldiken; Baburhan Guldiken; Muzaffer Demir; Levent Kabayel; Hulya Ozkan; Nilda Turgut; Remziye Hunkar; Selahattin Kat|
Related Documents :
|17276734 - The tnfalpha locus is altered in monocytes from patients with systemic lupus erythemato...
21801684 - La nlpc en décubitus dorsal modifié : notre expérience.
380854 - Antibodies to histones in systemic lupus erythematosus.
19839494 - Urticarial vasculitis: etiologies and clinical course.
8723124 - Incidence and spectrum of renal abnormalities in williams-beuren syndrome.
8605744 - Lymph nodes in the hepatoduodenal ligament: us appearances with ct and mr correlation.
|Type: Journal Article Date: 2011-02-18|
|Title: The journal of headache and pain Volume: 12 ISSN: 1129-2377 ISO Abbreviation: J Headache Pain Publication Date: 2011 Jun|
|Created Date: 2011-05-16 Completed Date: 2011-09-01 Revised Date: 2013-06-30|
Medline Journal Info:
|Nlm Unique ID: 100940562 Medline TA: J Headache Pain Country: Italy|
|Languages: eng Pagination: 355-60 Citation Subset: IM|
|Department of Endocrinology, Trakya University Medical Faculty, Edirne, Turkey.|
|APA/MLA Format Download EndNote Download BibTex|
Atherosclerosis / epidemiology, metabolism*
C-Reactive Protein / metabolism
CD40 Ligand / blood*
Migraine Disorders / epidemiology, metabolism*
Prolactin / blood*
Vasculitis / epidemiology, metabolism*
|147205-72-9/CD40 Ligand; 9002-62-4/Prolactin; 9007-41-4/C-Reactive Protein|
Journal ID (nlm-ta): J Headache Pain
Publisher: Springer Milan, Milan
© The Author(s) 2011
Received Day: 4 Month: 12 Year: 2010
Accepted Day: 25 Month: 1 Year: 2011
Electronic publication date: Day: 18 Month: 2 Year: 2011
pmc-release publication date: Day: 18 Month: 2 Year: 2011
Print publication date: Month: 6 Year: 2011
Volume: 12-12 Issue: 3
First Page: 355 Last Page: 360
PubMed Id: 21331754
Publisher Id: 306
|Soluble CD40 ligand and prolactin levels in migraine patients during interictal period|
Address: +90-5322578312 email@example.com
1Department of Endocrinology, Trakya University Medical Faculty, Edirne, Turkey
2Department of Neurology, Trakya University Medical Faculty, 22100 Edirne, Turkey
3Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey
4Department of Neurology, Social Security Hospital of Edirne, Edirne, Turkey
Migraine is a kind of headache which is caused by the alterations in trigeminovascular system, but the pathophysiological mechanisms have not still been fully delineated. Today, it is known that the vascular alterations are not limited to cranial vessels, and migraine is suggested to be a systemic vasculopathy . The vasculopathy of migraine is thought to reflect the endothelial dysfunction and impaired vascular reactivity. The activation of the platelets and the coagulation factors , the increased secretion of von Willebrand factor and tissue plasminogen activator from endothelium , the decrease in the circulating endothelial progenitor cells , which are all seen in migraine, support this theory. The demonstration of similar C-reactive protein (CRP) levels in migraineurs and healthy control subjects in recent studies [5, 6], although it had been found high in previous studies [7–9], necessitates new investigations and data about this issue.
The increasing number of studies in the past decade showed that the risk of cardiovascular disease is increased in migraine [10–13]. Cytokines and cytokine-inducible inflammatory molecules are predictors of cardiovascular events. Elevated high-sensitivity CRP (hsCRP), interleukin 6 and soluble CD40 ligand (sCD40L) levels are associated with the increased risk of cardiovascular disease [14, 15]. Soluble CD40L is a ligand of glycoprotein IIb-IIIa receptor and is involved in thrombus stabilization and platelet activation. It is a reliable predictor of cardiovascular disease .
Prolactin, secreted from anterior pituitary gland and meanwhile also synthesized by various immune system cells, has been reported to cause a tendency to the cardiovascular diseases. On the other hand, hyperprolactinemia induces migraine attacks  and also plays a role in other primary headache syndromes . It is known that dopaminergic dysfunction is responsible from autonomic symptoms such as nausea and yawning .
In this study, we aimed to investigate the sCD40L, prolactin and hsCRP levels in migraine patients during interictal period and their relationship with migraine subtypes and attack frequency.
Fifty female migraine patients and age-matched 25 female control subjects were enrolled in the study. Migraine diagnosis was settled according to the International Classification of Headache Disorders-II diagnostic criteria . Twenty-three patients had migraine with aura, while the rest had migraine without aura. The control subjects were enrolled as healthy individuals who had no headache of any kind. The study was approved by the local Ethics Committee, and all patients gave their informed consent to participate in the study. Exclusion criteria included pregnancy, disorders and drugs which affect the prolactin levels such as butyrophenones, phenothyozines, reserpine or methyldopa, history of prolactinoma, hypothyroidism, chronic renal failure and cirrhosis. A questionnaire was completed about the existence of vascular risk factors such as hypertension, diabetes, smoking and family history of cardiovascular diseases. Migraine headache attack frequency was noted as the number of attacks per month. Body mass index (BMI) was calculated on the basis of World Health Organization (WHO) recommendations.
Serum samples were collected from an antecubital vein without using a tourniquet, between 08:30 and 09:00 a.m. after overnight fasting. For hsCRP, sCD40L and prolactin, venous blood samples were centrifuged within 15 min at 3,000 rpm for 10 min, and the supernatant serum samples were transferred into polypropylene tubes at −80°C until the assays were performed. Soluble CD40L and hsCRP levels were measured by ELISA (Biosource, Immunoassay-kit, USA; DRG Inc., USA, respectively) and prolactin levels by chemiluminesense immunoassay (DPC, Immulite 2000, USA). The participants’ serum fasting glucose levels were measured using the glucose oxidase technique (Konelab 60, Finland). Cholesterol esterase enzymatic assays (Konelab 60, Finland) were used to measure total cholesterol and high-density lipoprotein-cholesterol (HDL-C). Triglyceride levels were measured by the lipase technique (Konelab 60, Finland). Low-density lipoprotein-cholesterol (LDL-C) levels were calculated according to Friedewald’s formula. Values of the platelet count and mean platelet volume were obtained from whole blood count analysis.
All statistical analyses were performed by using SPSS 11.5 software for Windows. Data were expressed as mean ± SD. The normality of the distribution of all variables was assessed by the Kolmogorov–Smirnov test. Student’s t test and Pearson correlation analyses were used for normally distributed variables. The Mann–Whitney U test and Spearman rank correlation test were used for non-parametric variables. Logistic regression model was performed for adjusting for BMI. P values <0.05 were considered statistically significant.
The characteristics of the migraine patients and the control subjects are shown in Table 1. Age, anthropometric values, blood pressure, serum fasting glucose and lipid levels did not differ between the two groups. BMI was higher in the migraine group (p < 0.05). No difference was found between the prolactin levels of the migraine patients and the controls. The sCD40L levels were significantly higher in migraine patients (p < 0.001). High-sensitivity CRP levels showed no difference between the groups. There was no correlation between the prolactin, sCD40L and hs-CRP levels in migraine patients (p > 0.05, for all). Soluble CD40L remained significantly high in the migraine group after adjusting for BMI of both the groups (p = 0.002). Mean platelet volume of migraine patients was significantly higher than that of the control group (p < 0.05) and was correlated with sCD40L levels (r = 0.362, p < 0.05).
No difference was found between migraine with aura and migraine without aura groups regarding the sCD40L, hsCRP and prolactin levels (Table 2). When the migraine patients were subdivided according the attack frequency, sCD40L, hsCRP and prolactin levels were indifferent among the frequent (4 or more attacks/month) and seldom (less than 4 attacks/month) attack groups (Table 3). Family history of migraine and cardiovascular disease were not associated with these parameters (p > 0.05, for all).
The main finding in our study was the elevated sCD40L levels in migraine patients. We consider that this is a new data related to the association of migraine and vascular diseases. There are several studies reporting the association of sCD40L with cardiovascular diseases. Soluble CD40L was suggested to be a predictor for myocardial infarction and stroke [21–23]. In the studies, where the acute coronary patients were enrolled, sCD40L was found as a marker of inflammatory thrombotic activity and found related with further increased cardiovascular events [21, 22]. Recently, CD40/CD40L pathway activation and a subsequent proinflamatory milieu were reported in diseases such as obesity [24, 25], diabetes mellitus  and hypertension . Whether migraine patients constitute a low- or high-risk group for cardiovascular disease is obscure, but high-sCD40L levels in migraine patients in our study support the presence of a vascular damage in migraine.
CD40L belongs to the tumor necrosis family and is a transmembrane protein expressed by heamatopoetic cell types such as T lymphocytes, monocytes and platelets as well as by nonheamatopoetic cells like endothelial and smooth muscle cells. Soluble form is particularly produced by platelet activation , is associated with plaque instability and is a predictor of the plaque complications [29, 30]. Moreover, CD40L is able to promote overexpression of tissue factor, a glycoprotein that has a crucial role in the activation of coagulation cascade . In order to clarify if the increase of sCD40L in migraine patients is concordant with platelet activation, we compared between the mean platelet volume of two groups. It is a reliable marker of platelet activation such as platelet aggregation, secretion of thromboxane A2, platelet factor 4 and thromboglobulin [32, 33]. We found that the mean platelet volume of migraine patients was significantly higher than that in the controls, and it was correlated with CD40L levels in migraine. This impresses that the high sCD40L levels in our study were mainly dependent on platelet activation.
Soluble CD40L additionally has inflammatory property including expression of adhesive molecule, chemokines and metalloproteinases , which is different from the inflammatory pathway of CRP [21, 27]. Matrixmetalloproteinase 9, whose levels are found high during migraine attacks, degrades laminin, collagen type IV, a critical component of brain blood levels . Soluble CD40L also induces the secretion of other proinflammatory cytokines such as interleukin 1 (IL-1), IL-6, IL-8, IL-10 and tumor necrosis factor (TNF) from monocytes , dentritic cells , fibroblasts  and epithelial cells . TNF alpha, IL-6, IL1 beta and IL10 were found to be increased during migraine attacks . In the present study, since we did not measure the levels of these proinflammatory cytokines, it is not possible to conclude any association of the proinflammatory property of sCD40L with the inflammation in migraine.
Another finding of our study is that the hsCRP levels of the migraineurs and the control cases were not significantly different. There are several studies reporting modest hsCRP increase in migraine patients, but this elevation was only noted in the migraine without aura group which was actually not associated with cardiovascular diseases [7–9]. A recent study carried on large number of case groups demonstrated no difference in hsCRP levels in migraine patients and non-migraineurs . The elevation of hsCRP levels is a marker of inflammatory process, especially in the cardiovascular diseases, infection and malignacies. However, as known, low CRP levels can also be seen in diseases with marked tissue inflammation such as systemic lupus erythematosus . Normal hsCRP value in migraine should not mean that there is no inflammation or no risk of cardiovascular disease in migraine. Other pathways, such as the inflammatory CD40 property, may be involved in the inflammatory process of migraine.
In our study, we found similar prolactin levels between the migraine and control groups during interictal period. Our results are concordant with two other studies reporting normal prolactin levels in migraine [41, 42]. It was hypothesized that the increased dopaminergic activity is responsible from prodromal, clinical and postdromal symptoms [19, 43] and, therefore, a decrease in prolactin levels should be expected during migraine attacks. Conveniently, Masoud and Fakharian  found a significant decrease in prolactin levels during the headache attack in migraineurs. Another study reported high prolactin levels during migraine attack, but the study was carried on subjects who had microprolactinomas . Since we measured the prolactin levels only during the interictal period, we could not compare our results with these two studies.
Although prolactin has been reported to create a tendency to the cardiovascular diseases [45–48], our study demonstrated no correlation of prolactin with sCD40L and hs-CRP. It is known that increased prolactin levels in cases with prolactinoma cause obesity, insulin resistance, an increase in homocysteine levels and low-grade inflammation and subsequently a tendency to cardiovascular diseases [46, 47]. High prolactin levels stimulating sympathetic tonus cause preeclempsia in pregnancy . Recently, a relationship was found between prolactin levels, blood pressure and arterial stiffness, and prolactin was accused of accelerated atherosclerosis in women with early menopause . The demonstration of the intense prolactin receptor expression on advanced human coronary atherosclerotic plaques supports the role of prolactin on the development of atherosclerosis .
The present study demonstrated that the sCD40L levels are elevated in female migraine patients during interictal period. The small number of the groups and the omission of other hormones, such as estrogens and progesterone, which influence the biologic action of prolactin were the limitations of the study. We consider that our findings should be supported by investigations during the attack period and also in male migraineurs. Further prospective studies are needed to clarify the mechanisms underlying the association between migraine and cardiovascular diseases.
Conflict of interest None.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.
|1..||Tietjen GE. Migraine as a systematic vasculopathyCephalalgiaYear: 200929989996|
|2..||D’Andrea G,Toldo M,Cortelazzo S,Milone FF. Platelet activity in migraineHeadacheYear: 19822220721210.1111/j.1526-4610.1982.hed2205207.x6216226|
|3..||Tietjen GE,Al Qasmi MM,Athanas K,Dafer RM,Khuder SA. Increased von Willebrand factor in migraineNeurologyYear: 20015733433611468324|
|4..||Lee ST,Chu K,Jung KH,Kim DH,Kim EH,Choe VN,Kim JH,Im WS,Kang L,Park JE,Park HJ,Park HK,Song EC,Lee SK,Kim M,Roh JK. Decreased number and function of endothelial progenitor cells in patients with migraineNeurologyYear: 2008701510151710.1212/01.wnl.0000294329.93565.9418354079|
|5..||Gudmundsson LS,Aspelund T,Scher AI,Thorgeirsson G,Johannsson M,Launer LJ,Gudnason V. C-reactive protein in migraine sufferers similar to that of non-migraineurs: the Reykjavik StudyCephalalgiaYear: 2009291301131010.1111/j.1468-2982.2009.01865.x19438929|
|6..||Guldiken B,Guldiken S,Demir M,Turgut N,Kabayel L,Ozkan H,Ozcelik E,Tugrul A. Insulin resistance and high sensitivity C-reactive protein in migraineCan J Neurol SciYear: 20083544845118973061|
|7..||Welch KM,Brandes AW,Salerno L,Brandes JL. C-reactive protein may be increased in migraine patients who present with complex clinical featuresHeadacheYear: 20064619719910.1111/j.1526-4610.2006.00330.x16492227|
|8..||Vanmolkot FH,Hoon JN. Increased C-reactive protein in young adult patients with migraineCephalalgiaYear: 20072784384610.1111/j.1468-2982.2007.01324.x17668468|
|9..||Kurth T, Ridker PM, Buring JE (2008) Migraine and biomarkers of cardiovascular disease in women. Cephalalgia 28:49–56|
|10..||Liew G,Wang JJ,Mitchell P. Migraine and coronary heart disease mortality: a prospective cohort studyCephalalgiaYear: 2007436837110.1111/j.1468-2982.2007.01298.x17346306|
|11..||Kurth T,Gaziano JM,Cook NR,Bubes V,Logroscino G,Diener HC,Buring JE. Migraine and risk of cardiovascular disease in menArch Intern MedYear: 200716779580110.1001/archinte.167.8.79517452542|
|12..||Agostoni E,Fumagalli L,Santoro P,Ferrarese C. Migraine and strokeNeurol SciYear: 200425Suppl 312312510.1007/s10072-004-0268-6|
|13..||Scher AI,Terwindt GM,Picavet HS,Verschuren WM,Ferrari MD,Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based studyNeurologyYear: 20056461462015728281|
|14..||Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart diseaseLancetYear: 200135894694810.1016/S0140-6736(01)06112-811583743|
|15..||Schönbeck U,Varo N,Libby P,Buring J,Ridker PM. Soluble CD40L and cardiovascular risk in womenCirculationYear: 20011042266226810.1161/hc4401.09944711696462|
|16..||Prasad KS,Andre P,Yan Y,Phillips DR. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic diseaseCurr Opin HematolYear: 20031035636110.1097/00062752-200309000-0000612913790|
|17..||Bosco D,Belfiore A,Fava A,Rose M,Plastino M,Ceccotti C,Mungari P,Iannacchero R,Lavano A. Relationship between high prolactin levels and migraine attacks in patients with microprolactinomaJ Headache PainYear: 2008910310710.1007/s10194-008-0016-z18256782|
|18..||Silberstein SD,Meriam GR. Sex hormones and headacheJ Pain Symptom ManageYear: 199389811410.1016/0885-3924(93)90107-78492007|
|19..||Fanciullacci M,Alessandri M,Del Rosso A. Dopamine involvement in the migraine attackFunct NeurolYear: 200015Suppl 317118111200788|
|20..||Headache Classification Sub-Committee of the International Headache Society (2004) International classification of headache disorders, 2nd edn. Cephalalgia 24:1–160|
|21..||Heeschen C,Dimmeler S,Hamm CW,Brand MJ,Boersma E,Zeiher AM,Simoons ML. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromesN Engl J MedYear: 20033481104111110.1056/NEJMoa02260012646667|
|22..||Varo N,Lemos JA,Libby P,Morrow DA,Murphy SA,Nuzzo R,Gibson CM,Cannon CP,Braunwald E,Schonbeck U. Soluble CD40L: risk prediction after acute coronary syndromesCirculationYear: 20031081049105210.1161/01.CIR.0000088521.04017.1312912804|
|23..||Garlichs CD,Kozina S,Fateh-Moghadam S,Handschu R,Tomandl B,Stumpf C,Eskafi S,Raaz D,Schmeisser A,Yilmaz A,Ludwig J,Neundorfer B,Daniel WG. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemiaStrokeYear: 2003341412141810.1161/01.STR.0000074032.64049.4712764232|
|24..||Unek IT,Bayraktar F,Solmaz D,Ellidokuz H,Sisman AR,Yuksel F,Yesil S. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese peopleClin Med ResYear: 20108899510.3121/cmr.2010.88920660932|
|25..||Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A (2007) The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 119(1):79–84|
|26..||Neubauer H,Setiadi P,Günesdogan B,Pinto A,Börgel J,Mügge A. Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in Type 2 diabetesDiabet MedYear: 20102738439010.1111/j.1464-5491.2010.02957.x20536508|
|27..||Yuan M,Ohishi M,Wang L,Raguki H,Wang H,Tao L,Ren J. Association between serum levels of soluble CD40/CD40 ligand and organ damage in hypertensive patientsClin Exp Pharmacol PhysiolYear: 20103784885110.1111/j.1440-1681.2010.05368.x20456428|
|28..||Andre P,Nannizzi-Alaimo L,Prasad SK,Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular diseaseCirculationYear: 200210689689910.1161/01.CIR.0000028962.04520.0112186789|
|29..||Mach F,Schonbeck U,Bonnefoy JY,Pober JS,Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factorCirculationYear: 1997963963999244201|
|30..||Blake GJ,Ostfeld RJ,Yucel EK,Varo N,Schonbeck U,Blake MA,Gerhard M,Ridker PM,Libby P,Lee RT. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRIArterioscler Thromb Vasc BiolYear: 200323e11e1410.1161/01.ATV.0000050143.22910.6212524242|
|31..||Bavendiek U,Libby P,Kilbride M,Reynolds R,Mackman N,Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1J Biol ChemYear: 2002277250322503910.1074/jbc.M20400320011978801|
|32..||Bath PM,Butterworth RJ. Platelet size: measurement, physiology and vascular diseaseBlood Coagul FibrinolysisYear: 1996715716110.1097/00001721-199603000-000118735807|
|33..||Sharp DB,Bath PMW,Martin JF,Martin JF,Beswick AD,Elwood PC. Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole bloodThromb HaemostYear: 1995747307358585014|
|34..||Leira R,Sobrino T,Rodriguez-Yanez M,Blanco M,Arias S,Castillo J. Mmp-9 immunoreactivity in acute migraineHeadacheYear: 20074769870210.1111/j.1526-4610.2006.00641.x17501851|
|35..||Kiener PA,Moran-Davis P,Rankin BM,Wahl AF,Aruffo A,Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytesJ ImmunolYear: 1995155491749257594496|
|36..||Caux C,Massacrier C,Vanbervliet B,Dubois B,Kooten C,Durand I,Banchereau J. Activation of human dendritic cells through CD40 cross-linkingJ Exp MedYear: 19941801263127210.1084/jem.180.4.12637523569|
|37..||Yellin MJ,Winikoff S,Fortune SM,Baum D,Crow MK,Lederman S,Chess L. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferationJ Leukoc BiolYear: 1995582092167543921|
|38..||Galy AH,Spits H. CD40 is functionally expressed on human thymic epithelial cellsJ ImmunolYear: 19921497757821378865|
|39..||Sarchielli P,Alberti A,Baldi A,Coppola F,Rossi C,Pierguidi L,Floridi A,Calabresi P. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictallyHeadacheYear: 20064620020710.1111/j.1526-4610.2006.00337.x16492228|
|40..||Carvalho JF,Hanaoka B,Szyper-Kravitz M,Shoenfeld Y. C-Reactive protein and its implications in systemic lupus erythematosusActa Reumatol PortYear: 20073231732218159197|
|41..||Awaki E,Takeshima T,Takahashi K. A neuroendocrinological study in female migraineurs: prolactin and thyroid stimulating hormone responsesCephalalgiaYear: 1989918719310.1046/j.1468-2982.1989.0903187.x2507160|
|42..||Murialdo G,Martignoni E,Maria A,Bonura ML,Sances G,Bono G,Polleri A. Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraineCephalalgiaYear: 19866434910.1046/j.1468-2982.1986.0601043.x3698093|
|43..||Peres MF,Sanchez del Rio M,Seabra ML,Tufik S,Abucham J,Cipolla-Neto J,Silberstein SD,Zukerman E. Hypothalamic involvement in chronic migraineJ Neurol Neurosurg PsychiatryYear: 20017174775110.1136/jnnp.71.6.74711723194|
|44..||Ali Masoud S,Fakharian E. Serum prolactin and migraineAnn Saudi MedYear: 20052548949116438460|
|45..||Georgiopoulos GA,Stamatelopoulos KS,Lambrinoudaki I,Lykka M,Kyrkou K,Rizos D,Creatsa M,Christodoulakos G,Alevizaki M,Sfikakis PP,Papamichael C. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factorsHypertensionYear: 2009549810510.1161/HYPERTENSIONAHA.109.13210019451414|
|46..||Serri O,Li L,Mamputu JC,Beuachamp MC,Maingrette F,Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapyClin EndocrinolYear: 200664336370|
|47..||Leaños-Miranda A,Márquez-Acosta J,Cárdenas-Mondragón GM,Chinolla-Arellano ZL,Rivera-Leaños R,Bermejo-Huerta S,Romero-Arauz J,Alvarez-Jiménez G,Ramos-León J,Ulloa-Aguirre A. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomesJ Clin Endocrinol MetabYear: 2008932492249910.1210/jc.2008-030518460570|
|48..||Reuwer AQ,Twickler MT,Hutten BA,Molema FW,Wareham NJ,Dallinga-Thie GM,Bogorad RL,Goffin V,Smink-Bol M,Kastelein JJ,Boekholdt SM,Khaw KT. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and womenCirc Cardiovasc GenetYear: 2009238939510.1161/CIRCGENETICS.109.85357220031611|
|49..||Yavuz D,Deyneli O,Akpinar I,Yildiz E,Gözü H,Sezgin O,Haklar G,Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal womenEur J EndocrinolYear: 200314918719310.1530/eje.0.149018712943520|
The clinical and laboratory characteristics of all participants
|Migraine subjects (n = 50)||Control subjects (n = 25)||p|
|Age (years)||38.0 ± 8.6||34.4 ± 7.8||Ns|
|Diabetes mellitus (%)||4.4||0||Ns|
|BMI (kg/m2)||26.54 ± 5.52||23.98 ± 3.18||<0.05|
|Systolic BP (mmHg)||118.09 ± 17.4||123.63 ± 23.77||Ns|
|Diastolic BP (mmHg)||77.44 ± 16.34||77.27 ± 11.03||Ns|
|Glucose (mg/dl)||91.76 ± 10.76||93.85 ± 22.8||Ns|
|Cholesterol (mg/dl)||189.88 ± 38.04||183.42 ± 40.28||Ns|
|Triglyceride (mg/dl)||106.21 ± 44.54||102.85 ± 53.97||Ns|
|LDL (mg/dl)||119.92 ± 32.38||111.68 ± 32.90||Ns|
|HDL (mg/dl)||50.03 ± 12.52||49.29 ± 15.88||Ns|
|Platelet (/mm3)||274361 ± 59207||263062 ± 60698||Ns|
|MPV (fL)||9.53 ± 1.4||8.7 ± 0.92||<0.05|
|Prolactin (ng/mL)||11.34 ± 8.63||10.89 ± 5.0||Ns|
|hs-CRP (mg/L)||4.28 ± 4.01||3.91 ± 3.89||Ns|
|sCD40L (ng/mL)||11.92 ± 5.26||7.72 ± 3.6||<0.001|
Ns non-significant, BP blood pressure, MPV mean platelet volume, hsCRP high-sensitivity C-reactive protein, sCD40L soluble CD40 ligand
Soluble CD40L, hsCRP and prolactin levels in migraineurs with aura and without aura subgroups
|Migraineurs with aura (n = 23)||Migraineurs without aura (n = 27)||p|
|sCD40L (ng/mL)||11.73 ± 4.52||12.08 ± 5.9||Ns|
|hsCRP (ng/L)||4.06 ± 3.98||4.46 ± 4.1||Ns|
|Prolactin (ng/mL)||9.45 ± 4.77||12.95 ± 10.74||Ns|
Ns non-significant, hsCRP high-sensitivity C-reactive protein, sCD40L soluble CD40 ligand
Soluble CD40L, hsCRP and prolactin levels in migraineurs with frequent (4 or more attacks/month) and seldom (less than 4 attacks/month) headache attacks
|Frequent migraine attacks (n = 33)||Seldom migraine attacks (n = 17)||p|
|sCD40L (ng/mL)||11.87 ± 4.55||14.09 ± 6.8||Ns|
|hsCRP (ng/L)||4.40 ± 3.72||4.76 ± 5.04||Ns|
|Prolactin (ng/mL)||9.70 ± 5.75||10.60 ± 3.74||Ns|
Ns non-significant, hsCRP high-sensitivity C-reactive protein, sCD40L soluble CD40 ligand
Keywords: Keywords Migraine, Prolactin, sCD40L, Subclinical atherosclerosis.
Previous Document: Headache prevalence in the population of L'Aquila (Italy) after the 2009 earthquake.
Next Document: Focus on the management of thunderclap headache: from nosography to treatment.